BR9810436A - Processo para a produção em larga escala de di (5'-tetrafosfato de uridina) e sais do mesmo - Google Patents

Processo para a produção em larga escala de di (5'-tetrafosfato de uridina) e sais do mesmo

Info

Publication number
BR9810436A
BR9810436A BR9810436-5A BR9810436A BR9810436A BR 9810436 A BR9810436 A BR 9810436A BR 9810436 A BR9810436 A BR 9810436A BR 9810436 A BR9810436 A BR 9810436A
Authority
BR
Brazil
Prior art keywords
sub
treatment
tetraphosphate
uridine
salts
Prior art date
Application number
BR9810436-5A
Other languages
English (en)
Other versions
BRPI9810436B1 (pt
Inventor
Benjamin R Yerxa
William Pendergast
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of BR9810436A publication Critical patent/BR9810436A/pt
Publication of BRPI9810436B1 publication Critical patent/BRPI9810436B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"PROCESSO PARA PRODUçãO EM LARGA ESCALA DE DI (5'-TETRAFOSFATO DE URIDINA) E SAIS DO MESMO" A presente invenção provê novos processos para síntese de dinucleotídeo terapêutico, P¹, P^ 4^-di (5'-tetrafosfato de uridina), e demonstra aplicabilidade para produção de grandes quantidades. Os processos da presente invenção reduzem, substancialmente, o período de tempo necessário para sintetizar tetrafosfato de diuridina, preferivelmente para três dias ou menos. Os novos sais de tetramónio e tetrassódio de P¹, P^ 4^-di (5'-tetrafosfato de uridina) da fórmula (I) preparados por estes processos são estáveis, solúveis, não tóxicos e fáceis de manusear durante fabricação. Na fórmula, I, X é Na, NH~ 4~ ou H, contanto que, todos os grupos X não sejam H.
BRPI9810436A 1997-07-25 1998-07-24 processo para a produção em larga escala de di (5'-tetrafosfato de uridina) e sais do mesmo BRPI9810436B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5414797P 1997-07-25 1997-07-25
PCT/US1998/015445 WO1999005155A2 (en) 1997-07-25 1998-07-24 Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof

Publications (2)

Publication Number Publication Date
BR9810436A true BR9810436A (pt) 2000-12-12
BRPI9810436B1 BRPI9810436B1 (pt) 2015-12-29

Family

ID=21989063

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9810436A BRPI9810436B1 (pt) 1997-07-25 1998-07-24 processo para a produção em larga escala de di (5'-tetrafosfato de uridina) e sais do mesmo

Country Status (17)

Country Link
US (1) US7432252B1 (pt)
EP (1) EP1012154B1 (pt)
JP (1) JP3723227B2 (pt)
KR (1) KR20010013797A (pt)
CN (1) CN1147502C (pt)
AT (1) ATE261982T1 (pt)
AU (1) AU747196B2 (pt)
BR (1) BRPI9810436B1 (pt)
CA (1) CA2295515C (pt)
DE (1) DE69822482T2 (pt)
DK (1) DK1012154T3 (pt)
ES (1) ES2217569T3 (pt)
HK (1) HK1028613A1 (pt)
NO (1) NO328229B1 (pt)
NZ (1) NZ501696A (pt)
PT (1) PT1012154E (pt)
WO (1) WO1999005155A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US7223744B2 (en) 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
EP1012154B1 (en) 1997-07-25 2004-03-17 Inspire Pharmaceuticals, Inc. Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof
US6872710B2 (en) 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
US6548658B2 (en) * 1997-07-25 2003-04-15 Inspire Pharmaceuticals, Inc. Di-(uridine 5′)-tetraphosphate and salts thereof
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
HU228681B1 (en) * 1998-10-02 2013-05-28 Yamasa Corp Crystal of diuridine tetraphosphate or salt thereof and method for preparing the same, and method for producing said compound
CN100354296C (zh) * 1998-10-02 2007-12-12 雅玛山酱油株式会社 二尿苷四磷酸或其盐的晶体和其制备方法、以及制备该化合物的方法
DE60006814T2 (de) * 1999-06-30 2004-05-19 Yamasa Corp., Choshi Dinucleotid-kristalle
WO2001056581A1 (fr) * 2000-02-04 2001-08-09 Kissei Pharmaceutical Co., Ltd. Preparation en poudre pour inhalation et inhalateur de poudre contenant cette preparation
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
CN1228053C (zh) * 2001-09-11 2005-11-23 参天制药株式会社 含有二尿苷磷酸的滴眼液
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
EP2045257B1 (en) 2006-07-26 2016-08-17 Yamasa Corporation Process for producing di(pyrimidine nucleoside 5'-)polyphosphate
JP5599078B2 (ja) * 2009-06-23 2014-10-01 ヤマサ醤油株式会社 アデノシンテトラホスフェート化合物の製造法
JP5956735B2 (ja) 2010-09-10 2016-07-27 参天製薬株式会社 Ｐ２ｙ２受容体作動薬およびヒアルロン酸またはその塩を組み合わせたことを特徴とするドライアイ治療剤
MX2013007502A (es) 2010-12-28 2013-08-01 Santen Pharmaceutical Co Ltd Solucion oftalmica que comprende diquafosol, metodo para producir la misma, y metodo para inhibir la formacion de precipitado insoluble.
CN102146111A (zh) * 2011-01-26 2011-08-10 北京润德康医药技术有限公司 一类新型二核苷酸化合物及其制备方法
EP2832359B1 (en) 2012-03-26 2018-11-14 Santen Pharmaceutical Co., Ltd. Diquafosol-containing eye drop
HUE055280T2 (hu) * 2016-10-25 2021-11-29 Yamasa Corp Eljárás P1, P4-di(uridin-5'-)tetrafoszfát tisztítására
KR102504764B1 (ko) * 2017-06-21 2023-03-02 주식회사 종근당 디뉴클레오사이드 폴리포스페이트 화합물의 제조방법
CN109305991B (zh) * 2017-07-27 2021-02-26 江苏恒瑞医药股份有限公司 一种p1,p4-二(尿苷5’-)四磷酸钠的制备方法
KR20180091689A (ko) 2017-11-06 2018-08-16 주식회사 종근당 무정형 디뉴클레오사이드 폴리포스페이트 화합물의 제조방법
TWI833406B (zh) 2018-02-28 2024-02-21 日商參天製藥股份有限公司 含有迪夸弗索（Ｄｉｑｕａｆｏｓｏｌ）及陽離子性聚合物之眼科用組合物
CN110540555B (zh) * 2018-05-28 2023-01-24 江苏恒瑞医药股份有限公司 一种游离核苷磷酸的方法
CN109021049B (zh) * 2018-06-14 2020-12-08 扬子江药业集团北京海燕药业有限公司 一种尿苷5′-二磷酸-苯并咪唑二钠的合成方法
CN113518646B (zh) 2019-02-27 2023-12-12 参天制药株式会社 含有地夸磷索或其盐，乙烯基系高分子及纤维素系高分子的眼科用组合物
KR20200106738A (ko) 2019-03-05 2020-09-15 주식회사 파마코스텍 P1,p4-디(우리딘 5'-)테트라포스페이트, 이의 염 또는 이의 수화물의 신규한 제조방법
CN110590887B (zh) * 2019-09-04 2020-12-15 江苏金殳医药科技有限公司 一种磷酸酯的制备方法
KR20210077946A (ko) 2019-12-18 2021-06-28 주식회사 종근당 우리딘 5’-디인산(udp), 이의 염 또는 이의 수화물의 제조방법
KR20210110055A (ko) * 2020-02-28 2021-09-07 주식회사 종근당바이오 P1, p4-디(우리딘 5'-)테트라포스페이트 나트륨염 4 수화물 결정형 a의 제조방법
CN111662350B (zh) * 2020-07-07 2022-06-07 南京宸翔医药研究有限责任公司 一种绿色化智能化高纯度地夸磷索四钠的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639562A (en) 1970-04-29 1972-02-01 Smith Kline French Lab Vaginal suppositories and impregnated tampons
US3639561A (en) 1970-04-29 1972-02-01 Smith Kline French Lab Vaginal suppositories and impregnated tampons
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
JPH05346549A (ja) 1992-04-17 1993-12-27 Canon Inc 走査光学装置
WO1995010538A1 (en) 1993-10-15 1995-04-20 The University Of North Carolina At Chapel Hill Dna encoding the human p2u receptor and null cells expressing p2u receptors
US5656256A (en) 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
JP3519199B2 (ja) 1996-02-06 2004-04-12 株式会社ソニー・コンピュータエンタテインメント 画像生成装置
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
CN1229114C (zh) * 1996-03-27 2005-11-30 印斯拜尔药品股份有限公司 用三磷酸尿苷和相关化合物治疗纤毛运动障碍的方法
US5837861A (en) 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5968913A (en) 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US5962432A (en) 1996-07-03 1999-10-05 Inspire Pharmaceuticals, Inc. Sterilized, isotonic and pH-adjusted pharmaceutical formulation of uridine triphosphate
US5789391A (en) 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
WO1998015835A1 (en) 1996-10-08 1998-04-16 Inspire Pharmaceuticals, Inc. Method of early lung cancer detection via sputum induction and analysis of sputum to detect cancer associated substances
US6159952A (en) 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds
CN1262556C (zh) * 1997-02-06 2006-07-05 印斯拜尔药品股份有限公司 特定的二核苷酸和它们作为粘膜纤毛清除和纤毛颤动频率调节剂的应用
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
EP1012154B1 (en) 1997-07-25 2004-03-17 Inspire Pharmaceuticals, Inc. Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof
AU9124998A (en) 1997-08-29 1999-03-16 Inspire Pharmaceuticals Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung iseases
CA2332540A1 (en) 1998-05-22 1999-12-02 Benjamin R. Yerxa Therapeutic dinucleotide and derivatives
US6294188B1 (en) 1998-07-09 2001-09-25 Aviana Biopharm Inc. Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women
GB9827477D0 (en) 1998-12-15 1999-02-10 Kalon Limited Paint
JP2002533110A (ja) 1998-12-23 2002-10-08 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Ｇタンパク質共役レセプターを使用した目的とする遺伝子の導入
AU3612600A (en) 1999-02-26 2000-09-14 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof

Also Published As

Publication number Publication date
DE69822482D1 (de) 2004-04-22
HK1028613A1 (en) 2001-02-23
NO996189L (no) 2000-03-27
DK1012154T3 (da) 2004-07-26
ATE261982T1 (de) 2004-04-15
AU8590398A (en) 1999-02-16
WO1999005155A2 (en) 1999-02-04
NO996189D0 (no) 1999-12-14
US7432252B1 (en) 2008-10-07
EP1012154B1 (en) 2004-03-17
DE69822482T2 (de) 2005-03-03
CN1265114A (zh) 2000-08-30
KR20010013797A (ko) 2001-02-26
CA2295515C (en) 2006-03-14
NO328229B1 (no) 2010-01-11
NZ501696A (en) 2001-08-31
AU747196B2 (en) 2002-05-09
JP2001510484A (ja) 2001-07-31
CA2295515A1 (en) 1999-02-04
WO1999005155A3 (en) 1999-06-24
CN1147502C (zh) 2004-04-28
EP1012154A2 (en) 2000-06-28
JP3723227B2 (ja) 2005-12-07
ES2217569T3 (es) 2004-11-01
BRPI9810436B1 (pt) 2015-12-29
PT1012154E (pt) 2004-08-31

Similar Documents

Publication Publication Date Title
BR9810436A (pt) Processo para a produção em larga escala de di (5'-tetrafosfato de uridina) e sais do mesmo
BR9915636A (pt) Método para promover secreções cervicais e vaginais
BR9809562A (pt) Método de tratar doença de secura ocular com agonistas receptores purinérgicos
BRPI0011856B8 (pt) agonistas de receptor a2a de n-pirazol
BR0011854A (pt) Agonistas de receptores de a2a de c-pirazola
ES2061416T1 (es) Ribocimas modificadas.
BR0111912A (pt) Derivados de purinas
DE60144479D1 (pt)
BR9811876A (pt) Uso de compostos contendo citidina e contendo citosina como tratamento para exposiçào a estimulante
MXPA01008547A (es) Metodo para promover la hidratacion de mucosas con ciertos difosfatos de uridina, adenina y citidina, y analogos de estos.
WO1997035591B1 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
BR9806784A (pt) Modificações do 2-amino-4-(4-fluorobenzilamino)-1-etoxicarbonilamin obenzeno, bem como processo para a sua preparação
PT952835E (pt) Metodo de tratamento de doenca cardiaca causada por chlamidia pneumoniae
BR0112659A (pt) Processo para o tratamento de secura vaginal ou disfunção sexual em mulheres durante ou depois da menopausa e utilização do composto (diaminoidroxi)toremifeno ou de um sal, éster ou metabolito farmaceuticamente aceitável do mesmo
BR9812631A (pt) Tetraidro prostaglandinas substituìdas por c16-c20 aromáticos úteis como agonistas de fp
BRPI0415324A (pt) composto, processo para a produção de um composto, composição farmacêutica, uso de um composto e método para o tratamento de um sujeito que sofre de uma condição patológica ou doença susceptìvel de melhora por antagonismo de receptor de adenosina a2b
MY150408A (en) P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-ß-D-RIBOFURANOSYL)-3H-THIAZOLE[4,5-D]PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION
BR0110418A (pt) Método para tratamento da degeneração retiniana com agonistas do receptor purinérgico
US6696425B2 (en) Method of treating dry eye disease with purinergic receptor agonists
ATE394409T1 (de) Verfahren zur herstellung von purinnukleosiden
WO2001045691A3 (en) Method of treating gastrointestinal tract disease with purinergic receptor agonists
TR200402446T4 (tr) Servik aşınmanın tedavisi için sükralfatın kullanımı.
RU2008121953A (ru) Ирнк-ингибирование репликации вируса гриппа
CO4970704A1 (es) Solucion acuosa estable de em 12, y procedimiento de preparacion de dicha solucion
KR960031472A (ko) 1-엔(n)-에틸시소마이신의 제조방법

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AOS REQUISITOS DE NOVIDADE E ATIVIDADE INVENTIVA (ART. 8O COMBINADO COM ART. 11 E 13 DA LPI).

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2015, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2524 DE 21-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.